Akebia Therapeutics

Akebia Therapeutics(AKBA)

CAMBRIDGE, MA
Biotechnology

Focus: Small Molecules

Akebia Therapeutics is a life sciences company focused on Small Molecules.

HematologyNephrologyRespiratoryMetabolic DiseasesCardiovascular
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (1)

Pipeline & Clinical Trials

Phase 1
Clinical Trials (1)
NCT03799848A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function
Phase 1
Phase 1
Clinical Trials (1)
NCT02502500Effect of AKB-6548 on the Pharmacokinetics of Celecoxib
Phase 1
vadadustat
Healthy
Phase 1
Clinical Trials (1)
NCT03657290A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet
Phase 1
Clinical Trials (1)
NCT03992066Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
Phase 1
Clinical Trials (1)
NCT03801733Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin
Phase 1
Clinical Trials (1)
NCT03801759Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
Phase 1
Phase 1
Clinical Trials (1)
NCT02062203Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT07429006SAD and MAD Study of AKB-9090 in Healthy Adult Participants
Phase 1
Clinical Trials (1)
NCT03789032Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat
Phase 1
vadadustat reference tablets
Healthy
Phase 1
Clinical Trials (1)
NCT03639155A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults
Phase 1
AKB-6548 tablet, reference formulation given in the fasted state
Healthy
Phase 1
Clinical Trials (1)
NCT02412449Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects
Phase 1
Phase 1
Clinical Trials (1)
NCT02327546Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548
Phase 1
Phase 1
Clinical Trials (1)
NCT04299633Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat
Phase 1
Clinical Trials (1)
NCT03801746Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin
Phase 1
AKB-6548
Anemia
Phase 2
Clinical Trials (1)
NCT0226019316-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
Phase 2
Phase 2
Clinical Trials (1)
NCT04707573Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4
Phase 2
Vadadustat
Anemia
Phase 2
Clinical Trials (1)
NCT03799627Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa
Phase 2
AKB-6548
Anemia
Phase 2
Clinical Trials (1)
NCT0138109442-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
Phase 2
AKB-6548
Anemia
Phase 2
Clinical Trials (1)
NCT01235936Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
Phase 2
vadadustat
Anemia
Phase 2
Clinical Trials (1)
NCT03140722Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents
Phase 2
Vadadustat
Anemia
Phase 2
Clinical Trials (1)
NCT03054337Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
Phase 2
Clinical Trials (1)
NCT03217591A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
Phase 2
Clinical Trials (1)
NCT03254485A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Phase 2
Clinical Trials (1)
NCT07268638A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Phase 2
AKB-6548
Anemia
Phase 2
Clinical Trials (1)
NCT0190648920-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
Phase 2
Vadadustat
Anemia
Phase 2
Clinical Trials (1)
NCT03054350Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
Phase 2
Clinical Trials (1)
NCT07086755Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury
Phase 2/3
Clinical Trials (1)
NCT04707768Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mirceraยฎ) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
Phase 3
Clinical Trials (1)
NCT05082584Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents
Phase 3
Vadadustat
Anemia
Phase 3
Clinical Trials (1)
NCT02892149Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
Phase 3
Vadadustat
Anemia
Phase 3
Clinical Trials (1)
NCT02648347Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
Phase 3
Ferric Citrate 1 GM Oral Tablet [AURYXIA]
Anemia, Iron Deficiency
Phase 3
Clinical Trials (1)
NCT05085275Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
Phase 3
Vadadustat
Anemia
Phase 3
Clinical Trials (1)
NCT02865850Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
Phase 3
Clinical Trials (1)
NCT05082571Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease
Phase 3
Vadadustat
Anemia
Phase 3
Clinical Trials (1)
NCT02680574Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
Phase 3
Clinical Trials (1)
NCT06520826Vafseo Outcomes In-Center Experience
Phase 3
Vadadustat
Anemia
Phase 3
Clinical Trials (1)
NCT03242967Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
Phase 3
Erythropoiesis-Stimulating Agent
Anemia of Chronic Kidney Disease
Phase 3
Clinical Trials (1)
NCT06901505To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
Phase 3
Vadadustat
Anemia
Phase 3
Clinical Trials (1)
NCT04313153Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
Phase 3
Ferric Citrate 1 gram Oral Tablet
Hyperphosphatemia
Phase 4
Clinical Trials (1)
NCT04922645Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants
Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 1 approved product, 40 clinical trials
Top TAs: Nephrology
SEC Filings: 2 available
Portfolio Health
Growth1 (100%)
1 total products
Therapeutic Area Focus
Nephrology
1 marketed
Marketed
Pipeline

Financials (FY2025)

Revenue
$195M0%
R&D Spend
$63M(32%)0%
Net Income
-$52M
Cash
$43M